SCHEMBL2328757

SCHEMBL2328757

COP(=O)(CC(=O)c1cn(C)nc1C)OC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.44
ATM Q13315 1/20 0.42
NAMPT P43490 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.39
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
ALPL P05186 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 4/20 0.38
NPC1 O15118 2/20 0.38
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PROKR1 Q8TCW9 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325901 0.80 GAA (0.52) GAASMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL2328765 0.78 GAA (0.42) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL2325474 0.77 KLKB1 (0.47) ALDH1A1RAB9ANPC1POLBMEN1
SCHEMBL27755239 0.75 GAA (0.44) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL18994374 0.74 GAA (0.49) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL23366905 0.73 GAA (0.47) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL841632 0.73 GAA (0.51) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL13306677 0.73 ATM (0.48) GAAATMNAMPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL23354477 0.71 GAA (0.46) GAAATMNAMPTSMN1; SMN2ALDH1A1
SCHEMBL2326711 0.71 ALDH1A1 (0.33) GAASMN1; SMN2ALDH1A1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 GAA 3130/4885ATM 4244/4885NAMPT 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.